Aurora Cannabis Snags MedReleaf in $3.2 Billion Deal

James West
|

Midas Letter Chart (ACB:TSX,LEAF:TSX)

Aurora Cannabis Inc (TSE:ACB) (OTCQB:ACBFF) (FRA:21P) and MedReleaf Corp (TSE:LEAF) (OTCMKTS:MEDFF) (FRA:MEW) announced the biggest merger yet in the Canadian Cannabis sector in an all stock transaction valued at $3.2 billion.

The purchase price implies a premium of thirty-four percent over the average last 20 sessions share price, giving MedReleaf shareholders a major win at $29.45 a share.

“This is transformational transaction that brings together two pioneering cannabis comapnies, ” said Aurora CEO Terry Booth.

Neil Closner, MeReleaf’s CEO said “By combining with Aurora, an integrated producer with an exceptionally strong track record for execution, and deep domestic and international distribution capabilities, we will be ideally positioned to set the global standard for our industry at a pace that will be difficult to match.”

Listen to Aurora Chief Corporate Officer Cam Battley discuss the merger with MedReleaf on Midas Letter LIVE!.

James West

James West

Editor and Publisher

James West founded Midas Letter in 2008 and has since been covering the best of Canadian and US small cap companies. He covers global economics, monetary policy, geopolitical evolution, political corruption, commodities, cannabis and cryptocurrencies. As an active market participant, James is not a journalist and is invariably discussing markets...
More Info...

[email protected] | |

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Be the First to Hear from Midas Letter on Investment News, Videos, and More.